ArticleNeurosurgical review2026
The effectiveness of chemonucleolysis with condoliase for lumbar disc herniation in elderly patients over 70 years old.
Article in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemonucleolysis with condoliase is a novel minimally invasive treatment for lumbar disc herniation (LDH). However, the effectiveness in elderly population have not been established yet. Our study seeks to investigate the outcomes of condoliase treatment in patients over 70 years old by comparing with those under 70 years old. In a retrospective study, eligible patients with LDH who underwent intradiscal condoliase injection from July 2019 to December 2024 were divided into two groups: an elderly group aged ≥ 70 years and a younger group aged < 70 years. Baseline characteristics, clinical outcomes using visual analog scale (VAS) and Japanese Orthopaedic Association (JOA) scores, radiological findings, and adverse events were compared between the two groups. Of 172 patients, 36 (20.9%) were aged ≥ 70 years and 136 (79.1%) were aged < 70 years. At the 3-month follow-up, both the elderly and younger groups showed significant improvements in JOA scores (mean change: 4.2 vs. 5.5) and each VAS of symptoms (mean change: − 2.2 vs. − 2.1 for back pain, − 3.2 vs. − 3.7 for leg pain, − 2.4 vs. − 3.3 for leg numbness) with no significant differences between the groups. Similar improvements were observed at the 6 and 12 months. Remarkably, the elderly group showed a lower rate of additional surgical interventions after condoliase treatment. Condoliase treatment showed similarly favorable clinical outcomes in elderly patients aged ≥ 70 years compared with younger patients. Chemonucleolysis with condoliase may be a minimally invasive treatment option for elderly patients with LDH.
Indexed as
Identifiers
41896329What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.